Endocrinology

Part 2 of a Q&A with Elena Christofides, MD highlighting important discussions surrounding ADA 2021, including semaglutide and obesity treatments as they relate to T2D.

In part 1 of a Q&A, Elena Christofides, MD highlights important discussions surrounding ADA 2021, including cardiometabolic medicine and risk factors for T1D.

Investigative ORMD-0701 has potential to regulate the insulin-glucagon balance in patients.

Changes in physical activity and diet may be main cause for worsening of diabetes control.

Deepak Bhatt, MD, MPH, discusses the results of REDUCE-IT BMI, which examined effects of icosapent ethyl vs placebo based on baseline BMI, that he presented at ADA 2021.

Of the two diabetes treatments included in the study, patients with Gla-300 had lower recorded total health costs and greater commitment to treatment.

Researchers found a significant interaction between SGLT2 inhibitors based on age and eGFR.

Data show 37.5% of patients in study were found to have moderate to severe DD, with an average score of ≥2.

eGFR improved by 10.8% and creatinine decreased by 6.8% in patients who received PIT procedures.

Data show consistent benefit of finerenone on kidney and CV outcomes in patients with CKD and T2D, regardless of SGLT-2i use.

The COVID-19 pandemic has increased the usage of telemedicine tools in all medical fields.

Over half of patients attained target A1C <7%. while a third of patients attained target A1C of <8%.

Overweight/obese patients with elevated fasting blood glucose generally present with higher degrees of insulin resistance, inflammation, adverse cardiovascular disease risk profile.

A comparison of 3 standard dietary strategies for weight and glycemia control showed no difference in exercise metrics.

The ADA study represents the first randomized head-to-head trial directly compareding an FRC with a remix insulin analog in a population of adults with suboptimally controlled type 2 diabetes on basal insulin plus OADs.

New data show liraglutide reduced visceral, ectopic fat, with greater effects seen compared to weight loss.

Diabetes, obesity, and older age are considered main risk factors that yield non-responses to different HBV vaccines.

Ahead of ADA 2021, Dr. Thomas Wadden discusses the significance of the semaglutide 2.4 mg (Wegovy) approval for chronic weight management and Novo Nordisk's plans to evaluate an oral version.

A look at more than 300 clinical trials examining dietary supplements and alternative therapies for inducing weight loss has returned evidence detailing a lack of high-quality evidence related to the efficacy of these approaches.

Using 24 years of follow-up data from more than 12k adolescents provides insight into the impact of childhood BMI z-scores on risk of adverse health outcomes, including development of diabetes and premature myocardial infarction, in adulthood.

A pilot trial in 29 women suggests a combination of metformin and high dose fish oil could reduce triglycerides and ApoB-remnants among young women with polycystic ovary syndrome.

A study assessing levels of flourine in cosmetic products available in the US and Canada suggests many of these products could contain levels of chemicals that, over time, could cause harm.

A randomized trial comparing 3 dietary approaches, including 2 involving fasting, suggests the recently popularized approach does not provide any substantial benefits compared to a traditional diet.

A retrospective analysis of data from more than 30k patients with severe obesity suggests having a discussion about bariatric surgery with a clinician resulted in greater weight loss, regardless of if they underwent a bariatric procedure, but fewer than 9% had these discussions.

Data from the UK Biobank cohort details the increased risk of adverse health outcomes, including the development of diabetes and heart failure, among patients considered to have metabolically healthy obesity.